ArticleJournal of neuro-oncology2019
Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.
Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06271421 (Application of Nanoparticles for Cyclic Hyperthermia In Adjuvant Therapy of gLioblastoma Multiforme), which is not on this map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application of Nanoparticles for Cyclic Hyperthermia In Adjuvant Therapy of gLioblastoma Multiforme (ANCHIALE)
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review.Journal of neuro-oncology · 2021Pooled it
- Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.Advanced drug delivery reviews · 2020Pooled it
- Advances in Nanomedicine for Brain Tumors: Overcoming Biological Barriers, Targeting Strategies, and Future Directions.Current neurology and neuroscience reports · 2026Review
- Magnetic Hyperthermia via ZnPharmaceutics · 2026Article
- BBB-aware stimuli-responsive and biomimetic nanomedicines for glioblastoma.Chinese neurosurgical journal · 2026Review
- S1-4 aptamer-mediated iron oxide nanoparticles for targeted magnetic hyperthermia in MCF-7 breast cancer cells.The Journal of international medical research · 2026Article
- Magnetic Fields in Cancer Therapy: Mechanistic Insights, Signaling Pathways, and Evidence from Clinical and In Vitro Studies.Pharmaceutics · 2026Review
- Magnetic Field-Guided Magnetic Nanoparticles as Neurotherapeutics for Neurological Disorders and Glioblastoma.Life (Basel, Switzerland) · 2026Review
- Clinical GBM hybrid artificial intelligence for prescription dose recommendation and outcome prediction after gamma knife radiosurgery treatment: a proof-of-concept.Frontiers in oncology · 2026Article
- Cancer immunotherapy strategies based on transition‑metal medical materials: Still a long way to go (Review).International journal of oncology · 2026Review
- Clinical Applications and Future Prospects of Metallic Nanoparticles in Diagnosis and Therapy.International journal of nanomedicine · 2026Review
- Nanoparticle-mediated magnetic hyperthermia in the treatment of neurological disorders.Nanomedicine (London, England) · 2025Review
- Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems.Nanomedicine (London, England) · 2025Review
- From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer's Disease Landscape.Medicina (Kaunas, Lithuania) · 2025Review
- Mechanical Forces Guide Axon Growth through the Nigrostriatal Pathway in an Organotypic Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting the glioblastoma resection margin with locoregional nanotechnologies.Nature reviews. Clinical oncology · 2025Review
- Synthesis of ε-FeJournal of functional biomaterials · 2025Article
- State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Review
- Biotransformation and biological fate of magnetic iron oxide nanoparticles for biomedical research and clinical applications.Nanoscale advances · 2025Review
- Innovative dual-gene delivery platform using miR-124 and PD-1 via umbilical cord mesenchymal stem cells and exosome for glioblastoma therapy.Journal of experimental & clinical cancer research : CR · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an increasing interest in local tumor ablative treatment modalities that induce immunogenic cell death and the generation of antitumor immune responses.
methodsWe report six recurrent glioblastoma patients who were treated with intracavitary thermotherapy after coating the resection cavity wall with superparamagnetic iron oxide nanoparticles ("NanoPaste" technique). Patients underwent six 1-h hyperthermia sessions in an alternating magnetic field and, if possible, received concurrent fractionated radiotherapy at a dose of 39.6 Gy.
resultsThere were no major side effects during active treatment. However, after 2-5 months, patients developed increasing clinical symptoms. CT scans showed tumor flare reactions with prominent edema around nanoparticle deposits. Patients were treated with dexamethasone and, if necessary, underwent re-surgery to remove nanoparticles. Histopathology revealed sustained necrosis directly adjacent to aggregated nanoparticles without evidence for tumor activity. Immunohistochemistry showed upregulation of Caspase-3 and heat shock protein 70, prominent infiltration of macrophages with ingested nanoparticles and CD3
conclusionIntracavitary thermotherapy combined with radiotherapy can induce a prominent inflammatory reaction around the resection cavity which might trigger potent antitumor immune responses possibly leading to long-term stabilization of recurrent GBM patients. These results warrant further investigations in a prospective phase-I trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.